Oncology · Phase 2-3 · pulled 2026-11-06

Colorectal cancer: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of colorectal cancer (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Colorectal cancer: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	MD Anderson Cancer Center Houston, United States · 16 spellings merged	41 21 completed, 20 terminated	NCT05039177 NCT04660812 NCT03929666 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors completed 2025-06-24 NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer terminated 2025-06-17 Stop reason on the record: “Sponsor decision based on limited anti-cancer activity of TAK-186.” NCT05589597 EO4010 in Previously Treated Metastatic Colorectal Carcinoma terminated 2025-05-30 Stop reason on the record: “Sponsor decision to stop recruitment in context of overall EO4010 development goals. Stop of recruitment was not related to any safety concern, with the safety profile of EO4010 being benign”	2026-01-26	53 NCT04607421 NCT06324357 NCT05411718 NCT07446322	85
2	SCRI Oncology Partners Nashville, United States · 30 spellings merged	31 21 completed, 10 terminated	NCT04868877 NCT05198934 NCT05039177 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT05451849 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer terminated 2025-08-30 Stop reason on the record: “No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.”	2026-10-01	37 NCT05608044 NCT06324357 NCT07549412 NCT06824064	89
3	Hospital Universitari Vall d'Hebron Barcelona, Spain · 31 spellings merged	28 12 completed, 16 terminated	NCT04868877 NCT05589597 NCT04278144 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05589597 EO4010 in Previously Treated Metastatic Colorectal Carcinoma terminated 2025-05-30 Stop reason on the record: “Sponsor decision to stop recruitment in context of overall EO4010 development goals. Stop of recruitment was not related to any safety concern, with the safety profile of EO4010 being benign” NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors terminated 2025-02-14 Stop reason on the record: “Sponsor Decision” NCT04744831 Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer completed 2024-12-04 NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis” NCT05091346 A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors completed 2024-10-15	2026-10-01	28 NCT05608044 NCT04607421 NCT06324357 NCT07549412	78
4	Seoul National University Hospital Seoul, South Korea · 23 spellings merged	21 14 completed, 7 terminated	NCT04868877 NCT05198934 NCT06714292 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT06714292 Fluorescent Approach for Refined Endoscopic Marking With Clip Localization and Identification Procedure completed 2025-11-19 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT05480306 Phase 2 Study of DKN-01 in Colorectal Cancer completed 2025-07-10	2026-10-01	20 NCT04607421 NCT06324357 NCT07549412 NCT06997497	90
5	Memorial Sloan Kettering Cancer Center New York, United States · 10 spellings merged	20 12 completed, 8 terminated	NCT04457284 NCT03929666 NCT05641896 6 trials with titles NCT04457284 Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer completed 2026-06-17 NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT05641896 Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers completed 2025-06-30 NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21 NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors terminated 2025-02-14 Stop reason on the record: “Sponsor Decision” NCT04666688 LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors completed 2024-12-12	2026-06-17	32 NCT06529523 NCT05608044 NCT04607421 NCT06324357	81
6	Hospital Universitario 12 de Octubre Madrid, Spain · 8 spellings merged	19 11 completed, 8 terminated	NCT04868877 NCT05625932 NCT05983367 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05625932 TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer completed 2025-06-04 NCT05983367 A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer terminated 2025-03-31 Stop reason on the record: “At the time of the primary analysis, results did not meet the primary endpoint” NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21 NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors terminated 2025-02-14 Stop reason on the record: “Sponsor Decision” NCT04744831 Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer completed 2024-12-04	2026-10-01	20 NCT04607421 NCT06324357 NCT07549412 NCT06695845	81
7	Hospital Universitario HM Sanchinarro Madrid, Spain · 36 spellings merged	19 7 completed, 12 terminated	NCT04868877 NCT05546476 NCT03362177 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05546476 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 completed 2025-04-23 NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer completed 2025-01-09 NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors terminated 2024-11-29 Stop reason on the record: “Due to lack of expected efficacy shown at the time of the interim analysis” NCT05330429 Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) terminated 2024-06-26 Stop reason on the record: “Sponsor decision to terminate study” NCT05619172 A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer terminated 2024-06-05 Stop reason on the record: “Due to lack of efficacy shown at the time of the interim analysis.”	2026-10-01	18 NCT06324357 NCT06760819 NCT05086692 NCT07284849	72
8	Massachusetts General Hospital Boston, United States · 7 spellings merged	19 11 completed, 8 terminated	NCT05358249 NCT05039177 NCT03223779 6 trials with titles NCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation terminated 2026-09-28 Stop reason on the record: “Business reasons and not based on any safety concerns.” NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT03223779 Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer completed 2025-10-02 NCT05328908 A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer terminated 2025-07-14 NCT05641896 Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers completed 2025-06-30 NCT05731947 Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors terminated 2025-06-30 Stop reason on the record: “Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.”	2026-09-28	20 NCT07584226 NCT07216560 NCT03526835 NCT07284849	89
9	City of Hope Duarte, United States · 12 spellings merged	19 12 completed, 7 terminated	NCT05198934 NCT05039177 NCT04660812 6 trials with titles NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT03365882 S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery completed 2025-07-01 NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT05104567 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) completed 2024-09-09	2026-04-14	17 NCT05608044 NCT07271355 NCT06760819 NCT05319314	90
10	ASST Grande Ospedale Metropolitano Niguarda Milan, Italy · 18 spellings merged	17 11 completed, 6 terminated	NCT04868877 NCT05198934 NCT03803436 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT03803436 Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation completed 2025-10-31 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21 NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer completed 2025-01-09	2026-10-01	19 NCT05608044 NCT04607421 NCT07549412 NCT06997497	83
11	Sun Yat-sen University Cancer Center Guangzhou, China · 27 spellings merged	17 12 completed, 5 terminated	NCT06071052 NCT07320950 NCT05775900 6 trials with titles NCT06071052 TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens completed 2025-12-31 NCT07320950 Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients completed 2025-12-22 NCT05775900 Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer completed 2025-08-26 NCT05600309 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study completed 2025-02-21 NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21 NCT06834399 TATE and KN046 in MCRC terminated 2025-01-09 Stop reason on the record: “Business Operation Strategy Adjustment”	2025-12-31	27 NCT04607421 NCT07549412 NCT06997497 NCT06750094	93
12	Samsung Medical Center Seoul, South Korea · 7 spellings merged	15 10 completed, 5 terminated	NCT04868877 NCT05198934 NCT04660812 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT05480306 Phase 2 Study of DKN-01 in Colorectal Cancer completed 2025-07-10 NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer terminated 2025-06-17 Stop reason on the record: “Sponsor decision based on limited anti-cancer activity of TAK-186.” NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21	2026-10-01	18 NCT04607421 NCT07549412 NCT06760819 NCT06750094	87
13	Severance Hospital Yonsei University Health System Seoul, South Korea · 18 spellings merged	15 11 completed, 4 terminated	NCT04868877 NCT05198934 NCT04660812 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer terminated 2025-06-17 Stop reason on the record: “Sponsor decision based on limited anti-cancer activity of TAK-186.” NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21	2026-10-01	19 NCT04607421 NCT06324357 NCT07549412 NCT06760819	88
14	Asan Medical Center Seoul, South Korea · 9 spellings merged	15 10 completed, 5 terminated	NCT05198934 NCT04660812 NCT03929666 6 trials with titles NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT05480306 Phase 2 Study of DKN-01 in Colorectal Cancer completed 2025-07-10 NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer terminated 2025-06-17 Stop reason on the record: “Sponsor decision based on limited anti-cancer activity of TAK-186.” NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors terminated 2025-02-14 Stop reason on the record: “Sponsor Decision”	2026-04-14	17 NCT04607421 NCT06324357 NCT07549412 NCT06760819	90
15	Mayo Clinic Rochester, United States · 13 spellings merged	15 11 completed, 4 terminated	NCT05641896 NCT05243862 NCT05500508 6 trials with titles NCT05641896 Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers completed 2025-06-30 NCT05243862 Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. completed 2025-01-14 NCT05500508 Oral AMXT 1501 Dicaprate in Combination With IV DFMO terminated 2024-12-12 Stop reason on the record: “Required re-formulation of DFMO from IV to capsule to maintain safety” NCT05593328 Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation completed 2024-12-09 NCT04322539 A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer completed 2024-04-24 NCT03829410 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation completed 2024-01-29	2025-06-30	24 NCT04607421 NCT06997497 NCT06710756 NCT06973564	93
16	Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy · 18 spellings merged	13 10 completed, 3 terminated	NCT06578559 NCT04868877 NCT05198934 6 trials with titles NCT06578559 Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC completed 2026-10-20 NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT03803436 Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation completed 2025-10-31 NCT03519412 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status completed 2025-01-08 NCT04744831 Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer completed 2024-12-04	2026-10-20	18 NCT06760819 NCT06750094 NCT06662786 NCT05379595	88
17	Hospital General Universitario Gregorio Maranon Madrid, Spain · 12 spellings merged	13 8 completed, 5 terminated	NCT04868877 NCT04660812 NCT03797326 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT05091346 A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors completed 2024-10-15 NCT04776148 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) completed 2024-09-27 NCT05678257 A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer terminated 2024-08-29 Stop reason on the record: “A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendat”	2026-10-01	15 NCT04607421 NCT06324357 NCT06997497 NCT07284849	81
18	University of Michigan Ann Arbor, United States · 9 spellings merged	13 9 completed, 4 terminated	NCT05223036 NCT05198934 NCT05708950 6 trials with titles NCT05223036 Testing Obeticholic Acid for Familial Adenomatous Polyposis terminated 2026-04-17 Stop reason on the record: “Protocol has been completed prematurely due to poor accrual and study feasibility.” NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT03365882 S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery completed 2025-07-01 NCT04952753 Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC terminated 2025-01-20 Stop reason on the record: “The study was terminated early due to the halt of NIS793 treatment and urgent safety measures issued in July and August 2023, respectively, as continued evaluation of Standard of Care alone will not s” NCT04744831 Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer completed 2024-12-04	2026-04-17	14 NCT05608044 NCT06324357 NCT06750094 NCT06662786	78
19	Washington University School of Medicine St Louis, United States · 21 spellings merged	13 9 completed, 4 terminated	NCT05039177 NCT04660812 NCT03365882 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT03365882 S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery completed 2025-07-01 NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors completed 2025-01-13 NCT05593328 Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation completed 2024-12-09 NCT04383210 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors terminated 2024-02-28 Stop reason on the record: “Business decision”	2026-01-26	34 NCT07662031 NCT04607421 NCT07446322 NCT07397338	80
20	CHU Poitiers Poitiers, France · 15 spellings merged	12 8 completed, 4 terminated	NCT04868877 NCT04660812 NCT04705818 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT04705818 Combining Epigenetic And Immune Therapy to Beat Cancer. completed 2025-07-17 NCT03584711 FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation completed 2025-03-30 NCT03186326 Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer completed 2025-03-01 NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21	2026-10-01	12 NCT05608044 NCT06750094 NCT06662786 NCT04657068	90
21	Hôpital Européen Georges Pompidou Paris, France · 15 spellings merged	12 9 completed, 3 terminated	NCT04868877 NCT05198934 NCT03584711 6 trials with titles NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination terminated 2026-10-01 Stop reason on the record: “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will hav” NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT03584711 FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation completed 2025-03-30 NCT03186326 Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer completed 2025-03-01 NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21 NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer completed 2025-01-09	2026-10-01	10 NCT07549412 NCT05462613 NCT06997497 NCT04008797	84
22	Royal Marsden Hospital London, United Kingdom · 18 spellings merged	12 9 completed, 3 terminated	NCT05198934 NCT05064059 NCT04744831 6 trials with titles NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation completed 2026-04-14 NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21 NCT04744831 Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer completed 2024-12-04 NCT03981146 A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer completed 2024-11-26 NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT04776148 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) completed 2024-09-27	2026-04-14	11 NCT06324357 NCT06750094 NCT07284849 NCT04421820	81
23	Fred Hutchinson Cancer Center Seattle, United States · 17 spellings merged	12 6 completed, 6 terminated	NCT05039177 NCT05708950 NCT05733611 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT05733611 RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC terminated 2025-08-18 Stop reason on the record: “Business reasons.” NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer terminated 2025-06-17 Stop reason on the record: “Sponsor decision based on limited anti-cancer activity of TAK-186.” NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) completed 2025-02-21 NCT05500508 Oral AMXT 1501 Dicaprate in Combination With IV DFMO terminated 2024-12-12 Stop reason on the record: “Required re-formulation of DFMO from IV to capsule to maintain safety”	2026-01-26	18 NCT04607421 NCT06324357 NCT06997497 NCT06750094	85
24	Columbia University Medical Center New York, United States · 11 spellings merged	12 8 completed, 4 terminated	NCT04660812 NCT05480306 NCT04844073 6 trials with titles NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. completed 2025-09-05 NCT05480306 Phase 2 Study of DKN-01 in Colorectal Cancer completed 2025-07-10 NCT04844073 A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer terminated 2025-06-17 Stop reason on the record: “Sponsor decision based on limited anti-cancer activity of TAK-186.” NCT04666688 LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors completed 2024-12-12 NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) completed 2024-10-24 NCT03953235 A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens completed 2023-03-10	2025-09-05	8 NCT06662786 NCT05379595 NCT02000089 NCT04585750	85
25	Fox Chase Cancer Center Philadelphia, United States	12 9 completed, 3 terminated	NCT03929666 NCT03365882 NCT04332653 6 trials with titles NCT03929666 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer completed 2025-08-30 NCT03365882 S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery completed 2025-07-01 NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors completed 2025-01-13 NCT04109924 TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study completed 2024-09-05 NCT05330429 Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) terminated 2024-06-26 Stop reason on the record: “Sponsor decision to terminate study” NCT04383210 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors terminated 2024-02-28 Stop reason on the record: “Business decision”	2025-08-30	10 NCT06750094 NCT06662786 NCT02465060 NCT04094688	87

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Colorectal cancer: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Ji Won Park Seoul National University Hospital	5	NCT06714292 NCT03801915 NCT03366155 NCT03152565 NCT03158610	PMID 42962162 JCO clinical cancer informatics, 2026 · High match PMID 42958783 Annals of coloproctology, 2026 · High match PMID 42952309 Psycho-oncology, 2026 · High match
2	Yanhong Deng Sixth Affiliated Hospital, Sun Yat-sen University	3	NCT05775900 NCT03206151 NCT02909478	PMID 42928952 Frontiers in cell and developmental biology, 2026 · High match PMID 42890343 Gastroenterology report, 2026 · Medium match PMID 42846984 Gastroenterology report, 2026 · High match
3	Wells Messersmith University of Colorado, Denver	3	NCT05167409 NCT03781154 NCT03542877	PMID 42696650 Cancer research communications, 2026 · High match PMID 42663536 Clinical cancer research : an official journal of the American Association for Cancer Research, 2026 · High match PMID 29038296 Cancer immunology research, 2018 · High match
4	Josep Tabernero Vall d'Hebron Institute of Oncology	3	NCT04737187 NCT04495621 NCT03750786	PMID 42913633 Cancer cell, 2026 · High match PMID 42679330 JCO precision oncology, 2026 · High match PMID 42526180 ESMO open, 2026 · High match
5	Scott Kopetz MD Anderson	3	NCT05194735 NCT03981614 NCT03549338	PMID 42882841 Cancers, 2026 · High match PMID 42823331 Gut, 2026 · High match
6	Fortunato Ciardiello University of Campania Luigi Vanvitelli	3	NCT05223673 NCT05468892 NCT04561336	PMID 42907240 Clinical colorectal cancer, 2026 · Medium match PMID 42787936 The journal of liquid biopsy, 2026 · High match PMID 42661856 ESMO gastrointestinal oncology, 2026 · High match
7	Tim F Greten National Cancer Institute (NCI)	3	NCT04166383 NCT03785210 NCT03206073	PMID 38989414 Journal of gastrointestinal oncology, 2024 · High match PMID 36754451 Journal for immunotherapy of cancer, 2023 · High match PMID 33811727 Clinical and translational science, 2022 · High match
8	Andrés Muñoz Hospital Universitario Gregorio Marañón (Madrid)	2	NCT05625932 NCT05185947	No paper matched at High or Medium confidence
9	Jean-Baptiste Bachet Federation Francophone de Cancerologie Digestive	2	NCT03584711 NCT03186326	PMID 42957496 Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2026 · Medium match
10	Salvatore Siena Grande ospedale metropolitano Niguarda	2	NCT03519412 NCT03227926	PMID 42787936 The journal of liquid biopsy, 2026 · High match PMID 42661856 ESMO gastrointestinal oncology, 2026 · High match PMID 42617424 ESMO open, 2026 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.